Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin –angiotensin system in chronic heart failure? The culmination of a 20-year journey

This editorial refers to ‘Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril–valsartan or enalapril in the PIONEER-HF trial’††, by D.A. Morrowet al., on page3345.
Source: European Heart Journal - Category: Cardiology Source Type: research